Promoter Dhirendra Dubey increases stake in 3B BlackBio Dx

Promoter Dhirendra Dubey increased his shareholding in 3b blackbio dx by purchasing 1,000 equity shares on June 24, 2026. The transaction was executed through the open market, raising the promoter's stake to 8.45% of the total voting capital.

The disclosure was submitted under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Prior to this acquisition, Dubey held 7,24,098 shares, which accounted for 8.44% of the company's equity.

Shareholding Details

The following table outlines the changes in the promoter's shareholding following the transaction:

Description	Number of Shares	% of Total Share Capital	% of Diluted Share Capital
Holding Before Acquisition
Shares carrying voting rights	7,24,098	8.44	8.44
Acquisition Details
Shares acquired	1,000	0.011	0.011
Holding After Acquisition
Shares carrying voting rights	7,25,098	8.45	8.45

The company's equity share capital remains at Rs 8,58,26,700, consisting of 85,82,670 equity shares of Rs 10 each. There were no changes to the encumbered shares or convertible securities held by the acquirer.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.22%	-2.27%	-5.05%	-9.84%	-9.84%	-9.84%

Verici Dx, a developer of advanced clinical diagnostics for organ transplant, announced that collaborators will present new data on the predictive performance of its Tutivia test at the American Transplant Congress (ATC) Annual Meeting. The event is scheduled to take place from June 20–24, 2026, in Boston. The presentations will focus on the test's ability to predict acute kidney transplant rejection, which is critical for optimizing patient management and outcomes.

The two poster presentations will be delivered by leading transplant clinicians. They will describe the capabilities of Tutivia, a blood-based transcriptomics laboratory developed test (LDT). The test is designed to support precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemic–reperfusion injury. These conditions can confound conventional monitoring tools, including serum creatinine and cell-free DNA.

Presentation Details

The following table outlines the specific details of the poster presentations scheduled for Tuesday, June 23, 2026:

Title	Presenter	Session Date and Time	Location	Abstract Number
Evaluation of Tutivia™ Biomarker for Risk of Acute Rejection in Patients Experiencing Delayed Graft Function	Zahraa Fayez Hajjiri, MD, Medical Director, Transplant Nephrology, University of Illinois College of Medicine	Tuesday, June 23, 2026 from 2:30 PM - 3:30 PM	Exhibit Hall A	D107
Tutivia™ Molecular Risk Scores in Relation to BK Viral Activity, BK Virus Nephropathy, and Rejection Phenotypes in Kidney-Transplant Recipients	M. Javeed Ansari, MD, Transplant Nephrologist, Northwestern University Feinberg School of Medicine	Tuesday, June 23, 2026 from 2:30 PM - 3:30 PM	Exhibit Hall A	D099

Verici Dx plc combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence. This approach reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. The company's lead product, Tutivia, is a post-kidney transplant test focused on the early detection of acute rejection.